dihexa patent | 1401708-83-5 | BGC70883 DIHEXA 30ML LIQUID (20MG/ML, 600MG

Angelman Syndrome: Ube3a Loss of expression of the ubiquitin-protein ligase E3a (UBE3A) is associated with most cases of Angelman syndrome, which is a rare syndrome of developmental delay, ID and ASD (Buiting et al., 2018), which points to a highly regulated role of UBE3A in the organism

Smith I, Hyland K, Kendall B

PMID: 33987654 Anderson, P., et al

Each component within GLOW undergoes analytical verification, including: High-Performance Liquid Chromatography (HPLC) purity analysis Identity confirmation testing Batch-level traceability documentation Controlled manufacturing standards Sterile lyophilized vial packaging Certificates of Analysis are available upon request for documentation transparency

Pinch a fold of skin on the inner thigh, insert a 29 to 31 gauge insulin needle at a 45-degree angle, and inject slowly over 5 to 10 seconds